http://www.patentbaristas.com/archives/2009/04/09/ariad-patent-shot-down-lots-of-questions-remain/?utm_source=rss&utm_medium=rss&utm_campaign=ariad-patent-shot-down-lots-of-questions-remain Freshly Brewed Bio/Pharma Chat. Served Up Daily. Tue, 07 Feb 2012 11:57:58 +0000 hourly 1 http://wordpress.org/?v=3.3.1 http://www.patentbaristas.com/archives/2009/04/09/ariad-patent-shot-down-lots-of-questions-remain/comment-page-1/#comment-66901 Antibody Industry Week in Review | 4.13.09 — The Antibody Blog Mon, 13 Apr 2009 05:10:32 +0000 http://www.patentbaristas.com/?p=1351#comment-66901 [...] While not specifically antibody-related, the CAFC found that Ariad’s patent on methods of modulating the NF-kB pathway is invalid. [...] [...] While not specifically antibody-related, the CAFC found that Ariad’s patent on methods of modulating the NF-kB pathway is invalid. [...]

]]>